Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

Conditions

• Astrocytoma, IDH-Mutant, Grade 2
• Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant
• Recurrent Adult Diffuse Midline Glioma, H3 K27-Mutant
• Recurrent Astrocytoma, IDH-Mutant
• Recurrent Astrocytoma, IDH-Mutant, Grade 3
• Recurrent Astrocytoma, IDH-Mutant, Grade 4
• Recurrent Glioblastoma, IDH-Wildtype

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Biospecimen Collection — PROCEDURE
  Undergo blood and CSF sample collection
• Computed Tomography — PROCEDURE
  Undergo CT
• Intensity-Modulated Radiation Therapy — RADIATION
  Undergo IMRT
• Magnetic Resonance Imaging — PROCEDURE
  Undergo MRI
• Triapine — DRUG
  Given PO

Study Details

This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a period of improvement (recurrent). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Giving triapine in combination with radiation therapy may be safe, tolerable, and/or effective in treating patients with recurrent glioblastoma or astrocytoma.

Key Dates

Start date

Jul 30, 2025

Status verified

Jun 2026

Primary completion

Jun 30, 2027

Completion

Jun 30, 2027

Study Design

Enrollment

30 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Treatment (IMRT, triapine)
  Patients undergo IMRT QD 5 days per week (Monday-Friday) for a total of 10 treatment days over 2 weeks and receive triapine PO 2 hours prior to IMRT on each radiation treatment day in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or MRI throughout the study as well as blood sample collection during screening and on study. Patients may undergo CSF sample collection during screening.

Primary Outcome Measure

Incidence of dose-limiting toxicity [ Time Frame: Up to 28 days ]

Locations (42)

Find similar trials in Duarte, CA

Related Studies

• SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
  PHASE3 · Recruiting · Nuvation Bio Inc. · Birmingham, Alabama
• Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
  PHASE1/PHASE2 · Recruiting · National Cancer Institute (NCI) · Phoenix, Arizona
• Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy
  PHASE1 · Recruiting · Mayo Clinic · Jacksonville, Florida
• Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma
  PHASE1 · Recruiting · Northwestern University · Chicago, Illinois